Clinical Trial Update: Sipuleucel-T and Ipilimumab for Advanced Prostate Cancer [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating the combination of Sipuleucel-T and Ipilimumab for advanced or castration-resistant prostate cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer
• Prostate Cancer

Drugs mentioned

• Ipilimumab (Yervoy) (ipilimumab)
• sipuleucel-T (sipuleucel-T)

Snippet

Sponsor: Prostate Oncology Specialists, Inc. | Conditions: Prostate Cancer, Castrate Resistant Prostate Cancer | Phase 1 | Status: COMPLETED